J&J to spend $6.5bn on buying autoimmune-disease drugmaker Momenta
The deal is the latest sign that drug firms are seeking ways to bulk up even as the coronavirus pandemic upends other businesses
19 August 2020 - 17:03
London — Johnson & Johnson (J&J) has agreed to pay $6.5bn in cash to acquire Momenta Pharmaceuticals, a maker of autoimmune-disease drugs, in the largest pharmaceutical-industry merger in 2020.
Though the price tag falls short of some of the industry-shifting takeovers of recent years, the deal is the latest sign that drug companies are looking for ways to bulk up even as the coronavirus pandemic upends other businesses...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.